Neumora’s antidepressant stumbles in first Phase 3 trial readout

A brand new despair remedy developed by startup Neumora Therapeutics failed in a Part 3 scientific trial — the corporate’s first late-stage readout.

The drug, navacaprant, failed to point out a significant enchancment in despair scores in comparison with placebo, the corporate reported Thursday. Each the remedy group and the placebo group reported a 12.5-point discount of their scores. The drug additionally failed to point out a statistically vital enchancment on a scoring system measuring individuals’ capability to expertise pleasure, when in comparison with placebo.

That is the primary of three Part 3 research that Neumora has deliberate for navacaprant.